Upregulation of CTLA-4 in TNBC is a key mechanism of immune escape and may affect the efficacy of immunotherapy. Blocking CTLA-4 with inhibitors such as Ipilimumab may activate the immune response against tumor cells, offering hope for enhanced therapeutic efficacy. This evidence concerns the gene CTLA4 and neoplasm.